Nexvet Biopharma Plc (NVET) 8.61 $NVET
IPO Market 'Has Been a Lonely Place' but Pace Is Picking Up
at The Street - Fri Apr 17, 10:28AM CDT
Etsy and Virtu made a quite a splash with their Nasdaq debuts this week but is it enough to bring the U.S. IPO market out of its 2015 lull?
XBIT: 27.55 (+0.18), VIRT: 21.81 (-0.54), SHAK: 62.00 (+2.00), BOX: 18.29 (+0.37), ADRO: 38.17 (-0.50), ONCE: 64.79 (-0.25), CDTX: 14.94 (-0.11), ETSY: 25.12 (-0.63), CPPL: 26.86 (-0.10), SMMT: 11.00 (-0.59), LENS: 8.00 (+0.63), NVET: 8.61 (-0.27), GDDY: 24.77 (-0.01)
NexVet Bio hits bump in the road in developing lead product candidate
Seeking Alpha - at Seeking Alpha - Wed Apr 15, 11:28AM CDT
NVET: 8.61 (-0.27)
Nexvet Provides Update on NV-01 Program
GlobeNewswire - Wed Apr 15, 4:30AM CDT
Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapy developer, announced today an update on its development program for NV-01, an anti-nerve growth factor (NGF) monoclonal antibody (mAb) for the control of pain associated with canine osteoarthritis.
NVET: 8.61 (-0.27)
Nexvet Biopharma Appoints Dr. George Gunn as Chairman
GlobeNewswire - Wed Apr 01, 4:30AM CDT
Veterinary biologic therapy developer Nexvet Biopharma (Nasdaq:NVET) today announced it has appointed former Division Head of Novartis Animal Health Dr. George Gunn as non-executive chairman of the Nexvet Board of Directors. The appointment is effective from 31 March 2015.
LLY: 72.30 (+0.09), NVET: 8.61 (-0.27), NVS: 103.45 (-0.62)
Nexvet posts higher net loss of USD2.4m for Q2 fiscal 2015
M2 - Mon Mar 16, 4:05AM CDT
Nexvet Biopharma (Nasdaq:NVET), a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals, such as dogs and cats, stated on Friday that it recorded a net loss of USD2.4m for the three month periods ended 31 December 2014.
NVET: 8.61 (-0.27)
Nexvet misses by $1.63
Seeking Alpha - at Seeking Alpha - Fri Mar 13, 4:57AM CDT
NVET: 8.61 (-0.27)
Nexvet Reports Financial Results for Second Quarter of Fiscal Year 2015
GlobeNewswire - Fri Mar 13, 4:29AM CDT
Veterinary biologic therapy developer Nexvet Biopharma (Nasdaq:NVET) today announced its financial results for the three and six month periods ended December 31, 2014.
NVET: 8.61 (-0.27)
Nexvet Provides Update on Pivotal Field Safety and Efficacy Study for NV-01
GlobeNewswire - Mon Mar 09, 4:30AM CDT
Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapy developer, announced today an update on its pivotal field safety and efficacy study for its lead product candidate (NV-01), a novel monoclonal antibody (mAb) therapy for the control of pain associated with osteoarthritis in dogs.
NVET: 8.61 (-0.27)
Nexvet Biopharma Announces Closing of Initial Public Offering
GlobeNewswire - Wed Feb 11, 9:56AM CST
Veterinary biologic therapy developer Nexvet Biopharma (Nasdaq:NVET) today announced the closing of its initial public offering of 4,000,000 shares of its common stock at a price to the public of $10.00 per share, resulting in aggregate gross proceeds of $40 million, before underwriting discounts, commissions and estimated offering expenses. Nexvet's common stock is listed on The NASDAQ Global Market under the ticker symbol "NVET."
NVET: 8.61 (-0.27)
InsiderInsights.com Daily Round Up 2/10/15: ZIOP, WMS, R, MLNK
InsiderInsights - at Seeking Alpha - Wed Feb 11, 3:29AM CST
ZIOP: 10.88 (+0.03), TROV: 8.58 (-0.27), CRR: 33.68 (-0.12), SLG: 128.51 (+0.39), WMS: 28.56 (+0.53), MLNK: 3.75 (unch), RXN: 26.33 (+0.16), KTWO: 22.96 (-0.47), PANW: 153.87 (-0.50), YHOO: 43.97 (-0.52), WHR: 191.77 (-2.20), UA: 82.27 (-1.25), GILD: 104.18 (-1.02), R: 97.95 (+1.15), SIX: 49.97 (+1.37), DATA: 98.72 (-0.13), TW: 130.02 (+0.52), MA: 91.20 (+3.43), NVET: 8.61 (-0.27), IPGP: 97.60 (+1.46)
U.S. IPO Weekly Recap: Yield Takes The Field As Healthcare IPOs Need A Lifeline
Renaissance Capital IPO Research - at Seeking Alpha - Sat Feb 07, 1:32PM CST
Ten deals were on the IPO calendar to price this past week, but only three made it through as seven health care IPOs delayed going public. The year's first energy IPO was also the first to raise over $1 billion as natural gas MLP Columbia Pipeline...
DEA: 16.05 (-0.11), CPPL: 26.86 (-0.10), NVET: 8.61 (-0.27)
IPO Preview: Nexvet Biopharma Plc
IPOdesktop - Seeking Alpha - Thu Feb 05, 10:25AM CST
Based in Dublin, Ireland, Nexvet Biopharma plc (Pending: NVET ) scheduled a $58 million IPO on Nasdaq with a market capitalization of $160 million at a price range midpoint of $14.50 for Thursday, Feb. 5, 2015. The full IPO calendar is available...
NVET: 8.61 (-0.27)
Nexvet prices IPO
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 8:13AM CST
NVET: 8.61 (-0.27)
Nexvet Biopharma plc Announces Pricing of Initial Public Offering
GlobeNewswire - Thu Feb 05, 4:29AM CST
Veterinary biologic therapy developer Nexvet Biopharma (Nasdaq:NVET) today announced the pricing of its initial public offering of 4,000,000 ordinary shares at a price to the public of $10.00 per share. The shares are expected to begin trading on the NASDAQ Global Market on February 5, 2015 under the ticker symbol "NVET." All of the ordinary shares are being offered by Nexvet. In addition, Nexvet has granted the underwriters a 30-day option to purchase up to an additional 600,000 ordinary shares.
NVET: 8.61 (-0.27)
We Suggest Investors Hold Off On Nexvet Biopharma IPO
Don Dion - at Seeking Alpha - Wed Feb 04, 9:59AM CST
NVET: 8.61 (-0.27)
IPO Market Set For Another Surge In The Healthcare Sector
Renaissance Capital IPO Research - at Seeking Alpha - Mon Feb 02, 6:15PM CST
Ten IPOs are on the IPO calendar to raise $1.4 billion, led by an $800 million offering of natural gas pipelines. The MLP is joined by a government-focused REIT as the two dividend-producing IPOs seek to price late in the week. The remaining eight...
AVGR: 11.66 (+0.23), IDGX: (), SLWD: (), ITEK: 4.80 (-0.02), REDX: (), INOV: 25.83 (+0.17), PUMP: (), CBYL: 7.02 (-0.38), NVET: 8.61 (-0.27), AAAP: ()
IPO Market 'Has Been a Lonely Place' but Pace Is Picking Up
at The Street - Fri Apr 17, 10:28AM CDT
Etsy and Virtu made a quite a splash with their Nasdaq debuts this week but is it enough to bring the U.S. IPO market out of its 2015 lull?
XBIT: 27.55 (+0.18), VIRT: 21.81 (-0.54), SHAK: 62.00 (+2.00), BOX: 18.29 (+0.37), ADRO: 38.17 (-0.50), ONCE: 64.79 (-0.25), CDTX: 14.94 (-0.11), ETSY: 25.12 (-0.63), CPPL: 26.86 (-0.10), SMMT: 11.00 (-0.59), LENS: 8.00 (+0.63), NVET: 8.61 (-0.27), GDDY: 24.77 (-0.01)
NexVet Bio hits bump in the road in developing lead product candidate
Seeking Alpha - at Seeking Alpha - Wed Apr 15, 11:28AM CDT
NVET: 8.61 (-0.27)
Nexvet Provides Update on NV-01 Program
GlobeNewswire - Wed Apr 15, 4:30AM CDT
Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapy developer, announced today an update on its development program for NV-01, an anti-nerve growth factor (NGF) monoclonal antibody (mAb) for the control of pain associated with canine osteoarthritis.
NVET: 8.61 (-0.27)
Nexvet Biopharma Appoints Dr. George Gunn as Chairman
GlobeNewswire - Wed Apr 01, 4:30AM CDT
Veterinary biologic therapy developer Nexvet Biopharma (Nasdaq:NVET) today announced it has appointed former Division Head of Novartis Animal Health Dr. George Gunn as non-executive chairman of the Nexvet Board of Directors. The appointment is effective from 31 March 2015.
LLY: 72.30 (+0.09), NVET: 8.61 (-0.27), NVS: 103.45 (-0.62)
Nexvet posts higher net loss of USD2.4m for Q2 fiscal 2015
M2 - Mon Mar 16, 4:05AM CDT
Nexvet Biopharma (Nasdaq:NVET), a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals, such as dogs and cats, stated on Friday that it recorded a net loss of USD2.4m for the three month periods ended 31 December 2014.
NVET: 8.61 (-0.27)
Nexvet misses by $1.63
Seeking Alpha - at Seeking Alpha - Fri Mar 13, 4:57AM CDT
NVET: 8.61 (-0.27)
Nexvet Reports Financial Results for Second Quarter of Fiscal Year 2015
GlobeNewswire - Fri Mar 13, 4:29AM CDT
Veterinary biologic therapy developer Nexvet Biopharma (Nasdaq:NVET) today announced its financial results for the three and six month periods ended December 31, 2014.
NVET: 8.61 (-0.27)
Nexvet Provides Update on Pivotal Field Safety and Efficacy Study for NV-01
GlobeNewswire - Mon Mar 09, 4:30AM CDT
Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapy developer, announced today an update on its pivotal field safety and efficacy study for its lead product candidate (NV-01), a novel monoclonal antibody (mAb) therapy for the control of pain associated with osteoarthritis in dogs.
NVET: 8.61 (-0.27)
Nexvet Biopharma Announces Closing of Initial Public Offering
GlobeNewswire - Wed Feb 11, 9:56AM CST
Veterinary biologic therapy developer Nexvet Biopharma (Nasdaq:NVET) today announced the closing of its initial public offering of 4,000,000 shares of its common stock at a price to the public of $10.00 per share, resulting in aggregate gross proceeds of $40 million, before underwriting discounts, commissions and estimated offering expenses. Nexvet's common stock is listed on The NASDAQ Global Market under the ticker symbol "NVET."
NVET: 8.61 (-0.27)
InsiderInsights.com Daily Round Up 2/10/15: ZIOP, WMS, R, MLNK
InsiderInsights - at Seeking Alpha - Wed Feb 11, 3:29AM CST
ZIOP: 10.88 (+0.03), TROV: 8.58 (-0.27), CRR: 33.68 (-0.12), SLG: 128.51 (+0.39), WMS: 28.56 (+0.53), MLNK: 3.75 (unch), RXN: 26.33 (+0.16), KTWO: 22.96 (-0.47), PANW: 153.87 (-0.50), YHOO: 43.97 (-0.52), WHR: 191.77 (-2.20), UA: 82.27 (-1.25), GILD: 104.18 (-1.02), R: 97.95 (+1.15), SIX: 49.97 (+1.37), DATA: 98.72 (-0.13), TW: 130.02 (+0.52), MA: 91.20 (+3.43), NVET: 8.61 (-0.27), IPGP: 97.60 (+1.46)
U.S. IPO Weekly Recap: Yield Takes The Field As Healthcare IPOs Need A Lifeline
Renaissance Capital IPO Research - at Seeking Alpha - Sat Feb 07, 1:32PM CST
Ten deals were on the IPO calendar to price this past week, but only three made it through as seven health care IPOs delayed going public. The year's first energy IPO was also the first to raise over $1 billion as natural gas MLP Columbia Pipeline...
DEA: 16.05 (-0.11), CPPL: 26.86 (-0.10), NVET: 8.61 (-0.27)
IPO Preview: Nexvet Biopharma Plc
IPOdesktop - Seeking Alpha - Thu Feb 05, 10:25AM CST
Based in Dublin, Ireland, Nexvet Biopharma plc (Pending: NVET ) scheduled a $58 million IPO on Nasdaq with a market capitalization of $160 million at a price range midpoint of $14.50 for Thursday, Feb. 5, 2015. The full IPO calendar is available...
NVET: 8.61 (-0.27)
Nexvet prices IPO
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 8:13AM CST
NVET: 8.61 (-0.27)
Nexvet Biopharma plc Announces Pricing of Initial Public Offering
GlobeNewswire - Thu Feb 05, 4:29AM CST
Veterinary biologic therapy developer Nexvet Biopharma (Nasdaq:NVET) today announced the pricing of its initial public offering of 4,000,000 ordinary shares at a price to the public of $10.00 per share. The shares are expected to begin trading on the NASDAQ Global Market on February 5, 2015 under the ticker symbol "NVET." All of the ordinary shares are being offered by Nexvet. In addition, Nexvet has granted the underwriters a 30-day option to purchase up to an additional 600,000 ordinary shares.
NVET: 8.61 (-0.27)
We Suggest Investors Hold Off On Nexvet Biopharma IPO
Don Dion - at Seeking Alpha - Wed Feb 04, 9:59AM CST
NVET: 8.61 (-0.27)
IPO Market Set For Another Surge In The Healthcare Sector
Renaissance Capital IPO Research - at Seeking Alpha - Mon Feb 02, 6:15PM CST
Ten IPOs are on the IPO calendar to raise $1.4 billion, led by an $800 million offering of natural gas pipelines. The MLP is joined by a government-focused REIT as the two dividend-producing IPOs seek to price late in the week. The remaining eight...
AVGR: 11.66 (+0.23), IDGX: (), SLWD: (), ITEK: 4.80 (-0.02), REDX: (), INOV: 25.83 (+0.17), PUMP: (), CBYL: 7.02 (-0.38), NVET: 8.61 (-0.27), AAAP: ()
